Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (61-70 of 487) with videos related to

Pageof 49
Sort By:
Targeted Oncology|May 13, 2026
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding PatientsVivek Subbiah, Martin Dietrich
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2026
Should We Call Every Cancer a Rare Cancer?Chadi Nabhan, Vivek Subbiah
Cancer Discovery|April 4, 2022
Think Globally, Act Locally: Globalizing Precision OncologyJustin T Moyers, Vivek Subbiah
Cancer|September 28, 2023
TRKing sarcomas for precision medicine: Seek, and ye shall find!Justin T Moyers, Vivek Subbiah
Annals of Hematology|January 17, 2013
Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcomaVivek Subbiah, Ishwaria Mohan Subbiah
Cancer Discovery|February 26, 2020
Advances in Targeting RET-Dependent CancersVivek Subbiah, Gilbert J Cote
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 9, 2023
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E-Positive Adult and Pediatric Solid TumorsMohamed A Gouda, Vivek Subbiah
The Lancet. Oncology|February 8, 2018
Autoimmune hypophysitisEcaterina Ileana-Dumbrava, Vivek Subbiah
Cancer Journal (Sudbury, Mass.)|November 16, 2022
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision TherapyMohamed A Gouda, Vivek Subbiah
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Review: Ewing sarcoma treatment: a role for bisphosphonates?Vivek Subbiah, Joseph A Ludwig
Pageof 49

Showing results (61-70 of 487) with videos related to

Sort By:
Pageof 49
Targeted Oncology|May 13, 2026
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding PatientsVivek Subbiah, Martin Dietrich
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2026
Should We Call Every Cancer a Rare Cancer?Chadi Nabhan, Vivek Subbiah
Cancer Discovery|April 4, 2022
Think Globally, Act Locally: Globalizing Precision OncologyJustin T Moyers, Vivek Subbiah
Cancer|September 28, 2023
TRKing sarcomas for precision medicine: Seek, and ye shall find!Justin T Moyers, Vivek Subbiah
Annals of Hematology|January 17, 2013
Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcomaVivek Subbiah, Ishwaria Mohan Subbiah
Cancer Discovery|February 26, 2020
Advances in Targeting RET-Dependent CancersVivek Subbiah, Gilbert J Cote
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 9, 2023
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E-Positive Adult and Pediatric Solid TumorsMohamed A Gouda, Vivek Subbiah
The Lancet. Oncology|February 8, 2018
Autoimmune hypophysitisEcaterina Ileana-Dumbrava, Vivek Subbiah
Cancer Journal (Sudbury, Mass.)|November 16, 2022
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision TherapyMohamed A Gouda, Vivek Subbiah
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Review: Ewing sarcoma treatment: a role for bisphosphonates?Vivek Subbiah, Joseph A Ludwig
Pageof 49